Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Matfin, G.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Challenges in developing therapies for the metabolic syndrome

Glenn Matfin

Division of Endocrinology and Diabetes, Department of Medicine, New York University School of Medicine, New York, USA, glennmatfin{at}hotmail.com

Metabolic syndrome refers to a clustering of cardiovascular (CV) risk factors within a single individual. The established risk factor such as obesity, type 2 diabetes, dyslipidaemia, hypertension, and other emerging risk factors are closely related to intra-abdominal adiposity. Insulin resistance is also considered to be an important factor in the aetiology of this syndrome. The emerging risk factors include dysfunction of inflammation, coagulation, platelets, fibrinolysis, lipoproteins, endothelium, and other biological processes. Despite the potential utility of having all the CV risk factors under one umbrella term, debate continues about the very existence of the metabolic syndrome and its diagnostic criteria. Nevertheless, the component risk factors include some of the most common and serious public health challenges facing the developed and developing world today. By treating component risk factors, many existing therapies and new drugs in development target several aspects of metabolic syndrome. However, no drug is currently approved specifically for treatment of the metabolic syndrome.

The essential features of the metabolic syndrome, and some of the challenges in developing treatment options are discussed herein.

Key Words: diabetes • metabolic syndrome • obesity.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 4, 152-156 (2007)
DOI: 10.1177/14746514070070040301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?